JWH-200 (WIN 55,225)[1] is an analgesic chemical from the aminoalkylindole family that acts as a cannabinoid receptor agonist. Its binding affinity at the CB1 receptor is 42nM, around the same as that of THC,[2] but its analgesic potency in vivo was higher than that of other analogues with stronger CB1 binding affinity in vitro,[3] around 3 times that of THC but with less sedative effect,[4] most likely reflecting favourable pharmacokinetic characteristics. It was discovered by, and named after, Dr. John W. Huffman. On March 1, 2011, the United States DEA temporarily placed JWH-200 under Schedule I of the Controlled Substances Act (along with four other synthetic cannabinoids),[5]where it will remain for 12 months while it is researched and considered for permanent scheduling. In Canada, the drug is legal and not controlled (as of June 26, 2011).[6]
[edit] See also
[edit] References
- ^ Dutta, A. K.; Ryan, W.; Thomas, B. F.; Singer, M.; Compton, D. R.; Martin, B. R.; Razdan, R. K. (1997). "Synthesis, pharmacology, and molecular modeling of novel 4-alkyloxy indole derivatives related to cannabimimetic aminoalkyl indoles (AAIs)". Bioorganic & medicinal chemistry 5 (8): 1591–1600. doi:10.1016/S0968-0896(97)00111-9. PMID 9313864. edit
- ^ Huffman JW, Padgett LW. Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. Current Medicinal Chemistry, 2005; 12: 1395-1411.
- ^ Bell, MR; D'Ambra, TE; Kumar, V; Eissenstat, MA; Herrmann Jr, JL; Wetzel, JR; Rosi, D; Philion, RE et al (1991). "Antinociceptive (aminoalkyl)indoles". Journal of Medicinal Chemistry 34 (3): 1099–1110. doi:10.1021/jm00107a034. PMID 1900533.
- ^ Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR (1992). "Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol". Journal of Pharmacology and Experimental Therapeutics 263 (3): 1118–26. PMID 1335057.
- ^ http://www.federalregister.gov/articles/2011/03/01/2011-4428/schedules-of-controlled-substances-temporary-placement-of-five-synthetic-cannabinoids-into-schedule
- ^ http://laws.justice.gc.ca/en/C-38.8/
|
|
|
| Phytocannabinoids |
|
|
| Cannabinoid metabolites |
|
|
| Endogenous cannabinoids |
|
|
Synthetic cannabinoid
receptor agonists |
Classical cannabinoids
(Dibenzopyrans) |
|
|
| Nonclassical cannabinoids |
|
|
| Benzoylindoles |
|
|
| Naphthoylindoles |
|
|
| Naphthylmethylindoles |
|
|
| Phenylacetylindoles |
|
|
| Naphthoylpyrroles |
|
|
| Eicosanoids |
|
|
| Others |
|
|
|
Allosteric modulators of
cannabinoid receptors |
|
|
Endocannabinoid
activity enhancers |
|
|
Cannabinoid receptor
antagonists and
inverse agonists |
|
|
(what is this?) (verify)
